2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel - PubMed (original) (raw)

Guideline

. 2000 Oct 15;18(20):3558-85.

doi: 10.1200/JCO.2000.18.20.3558.

J O Armitage, C L Bennett, J Crawford, G D Demetri, P A Pizzo, C A Schiffer, T J Smith, G Somlo, J C Wade, J L Wade 3rd, R J Winn, A J Wozniak, M R Somerfield; American Society of Clinical Oncology

Affiliations

• PMID: 11032599
• DOI: 10.1200/JCO.2000.18.20.3558

Guideline

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

H Ozer et al. J Clin Oncol. 2000.

No abstract available

PubMed Disclaimer

Comment in

• Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.
  Balducci L, Lyman GH. Balducci L, et al. J Clin Oncol. 2001 Mar 1;19(5):1583-5. doi: 10.1200/JCO.2001.19.5.1583. J Clin Oncol. 2001. PMID: 11230505 No abstract available.

Similar articles

• Myeloid growth factors clinical practice guidelines in oncology.
  Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK; National Comprehensive Cancer Network. Crawford J, et al. J Natl Compr Canc Netw. 2005 Jul;3(4):540-55. doi: 10.6004/jnccn.2005.0030. J Natl Compr Canc Netw. 2005. PMID: 16038645 No abstract available.
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
  Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. Smith TJ, et al. J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682719
• Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
  Carrato A, Paz-Ares Rodríguez L, Rodríguez Lescure A, Casas Fernández de Tejerina AM, Díaz Rubio García E, Pérez Segura P, Constenla Figueiras M, García Carbonero R, Gómez Codina J, Lluch Hernández A, Maroto Rey JP, Martín Jiménez M, Mayordomo Cámara JI, Moreno Nogueira JA, Rueda Domínguez A; Spanish Society of Medical Oncology (SEOM). Carrato A, et al. Clin Transl Oncol. 2009 Jul;11(7):446-54. doi: 10.1007/s12094-009-0383-1. Clin Transl Oncol. 2009. PMID: 19574202
• Interactions between hematopoietic growth factors: the clinical role of combination biotherapy.
  Moore MA. Moore MA. Haematol Blood Transfus. 1989;32:11-21. doi: 10.1007/978-3-642-74621-5_2. Haematol Blood Transfus. 1989. PMID: 2483146 Review. No abstract available.

Cited by

• Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
  ELKasar AO, Hussien FZ, Abdel-Hamied HE, Saleh IG, Mahgoup EM, El-Arabey AA, Abd-Allah AR. ELKasar AO, et al. Cancer Chemother Pharmacol. 2024 Jun;93(6):541-554. doi: 10.1007/s00280-023-04620-w. Epub 2024 Feb 7. Cancer Chemother Pharmacol. 2024. PMID: 38324036 Clinical Trial.
• Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view.
  Gascón P, Awada A, Karihtala P, Lorenzen S, Minichsdorfer C. Gascón P, et al. Wien Klin Wochenschr. 2024 Jun;136(11-12):362-368. doi: 10.1007/s00508-023-02300-6. Epub 2023 Nov 27. Wien Klin Wochenschr. 2024. PMID: 38010512 Free PMC article. Review.
• Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
  Liang Z, He Y, Hu X. Liang Z, et al. Int J Mol Sci. 2022 Sep 13;23(18):10617. doi: 10.3390/ijms231810617. Int J Mol Sci. 2022. PMID: 36142538 Free PMC article. Review.
• Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34+ hematopoietic progenitors in an NHP model.
  D'Souza SS, Kumar A, Maufort J, Weinfurter JT, Raymond M, Strelchenko NS, Perrin E, Coonen J, Mejia A, Simmons HA, Torbett BE, Reynolds M, Thomson JA, Slukvin II. D'Souza SS, et al. Blood Adv. 2022 Sep 27;6(18):5267-5278. doi: 10.1182/bloodadvances.2022006984. Blood Adv. 2022. PMID: 35404997 Free PMC article.
• Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
  Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, Park JH, Douer D, Cicic D, Larson SM, Scheinberg DA, Jurcic JG. Rosenblat TL, et al. Clin Cancer Res. 2022 May 13;28(10):2030-2037. doi: 10.1158/1078-0432.CCR-21-3712. Clin Cancer Res. 2022. PMID: 35247915 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database